Search
for
Sort by
Research 811–840 of 1000+
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- JAK inhibitors and alopecia areata
- Recalcitrant alopecia areata responsive to leflunomide and anthralin—Potentially undiscovered JAK/STAT inhibitors?
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
- Effect of diode pumping solid state laser with wavelength 589 nm on gene expression of interlukine-2 and interferon-gamma Lowercase in human T-lymphocytes
- MiRNA-24 downregulates KLF6 affecting STAT3 protein expression and phosphorylation regulating melanogenesis in cashmere goat coat
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- An updated review of the sebaceous gland and its role in health and diseases Part 2: Pathophysiological clinical disorders of sebaceous glands
- Novel drugs of United States Food and Drug Administration approved in 2024
- Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
- Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
- AP-2α/AP-2β transcription factors are key regulators of epidermal homeostasis
- 496 Identification of differentially expressed miRNAs in alopecia areata that target immune-regulatory pathways
- Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
- Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men
- Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Characterization of Primary Cilia and Intraflagellar Transport 20 in the Epidermis
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Hair Dermal papilla maintain its hair inducing characteristics via autocrine exosomal miR-23a-3p
- Alopecia universalis following human papillomavirus vaccine administration: a case report
- Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Burden of immune-related skin diseases worldwide, 1991–2021: insights and prediction from the Global Burden of Disease Study
- 699 Effect of Prostaglandin D 2 on hair follicle growth and its impact on hair follicle stem/progenitor cells
- Global, Regional, and National Burden of Alopecia Areata in Children and Adolescents Aged 0-19 years from 1990 to 2021 and Projection to 2040
- Frontal fibrosing alopecia and lichen planopilaris: epidemiology, treatment, and remission rate (2014-2024)
- ASSOCIATION OF SYSTEMIC LUPUS ERYTHEMATOSUS AND CHRONIC GRANULOMATOUS DISEASE IN ADULTS: REPORT OF 2 CASES
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond